ArticleAnnals of surgical oncology2025
Epidemiology of Early Onset Prostate Cancer: Global Patterns, Risk Factors, and Projections Through 2040.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Comparative burden and projections of chewing tobacco-attributable lip/oral cavity and esophageal cancers: global and China-specific trends, 2000-2036.Annals of medicine · 2026Article
- Early-Onset Prostate Cancer: Epidemiology, Risk Factors, Biology, Clinical Features, Management, and Early Detection.MedComm · 2026Review
- Global Dual Incidence-Mortality Patterns of Prostate Cancer Across SDI Regions, 1990-2021: A Cross-Sectional Study Based on Global Burden of Disease 2021.Health science reports · 2026Article
- Microplastics in early-onset carcinogenesis.Carcinogenesis · 2026Review
- Global, regional, and national burden of early-onset prostate cancer, 1990-2021: a systematic analysis for the global burden of disease study 2021.World journal of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundScreening recommendations for early onset prostate cancer (EOPC) vary significantly across countries and regions, with differences in the recommended starting age and screening frequency. Given these variations, a comprehensive global analysis of EOPC epidemiology and disease burden is essential to inform evidence-based, region-specific screening and intervention strategies. PATIENTS AND
methodsUsing data from the Global Burden of Diseases Study (1990-2021), we analyzed EOPC incidence, mortality, and disability-adjusted life-years (DALYs) across 204 countries, stratified by Sociodemographic Index (SDI) levels. Age-standardized rates and trends were assessed through estimated annual percentage change values. Risk factors, including smoking, milk intake, and calcium intake, were evaluated. Frontier analysis identified regions needing urgent intervention, while Bayesian age-period-cohort modeling projected EOPC trends through 2040.
resultsIn 2021, there were 58,694 new EOPC cases and 7927 related deaths globally. The highest burden was observed in high-SDI regions. Incidence, mortality, and DALYs increased across most SDI regions, except for a decline in mortality in high-SDI areas. Age-specific analysis showed rising EOPC burden across all age groups from 1990 to 2021, with the sharpest increases in the 45-49 and 50-54 years age groups. Risk factor analysis attributed 1% of DALYs to smoking, while low milk and calcium intake were protective (-10.2 and -2.8%, respectively). Projections indicate a continued rise in global EOPC burden through 2040.
conclusionsThis study provides critical insights into the global burden of EOPC, emphasizing the need for region-specific screening and prevention strategies to mitigate its impact.
Indexed as
Identifiers
40553361What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.